Hem › Icke-småcellig lungcancer › North Carolina › Winston-Salem
Kliniska studier för Icke-småcellig lungcancer i Winston-Salem, NC
12 studier för Icke-småcellig lungcancer söker deltagare vid platser i och runt Winston-Salem (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekryterarFas 3
- Wake Forest University Health Sciences, Winston-Salem
- Wake Forest University at Clemmons, Clemmons · 9 mi bort
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RekryterarFas 3
- Novant Health Forsyth Medical Center ( Site 0166), Winston-Salem
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
RekryterarFas 3
- Novant Health Pharmacy Oncology Specialists, Winston-Salem
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
RekryterarFas 3
- Novant Health Pharmacy Oncology Specialists, Winston-Salem
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
RekryterarFas 2
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RekryterarFas 2
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
RekryterarFas 2
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
RekryterarFas 3
- Atrium Health Wake Forest Baptist, Winston-Salem
Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study
RekryterarObservationsstudie
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
RekryterarFas 2
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RekryterarObservationsstudie
- Wake Forest NCORP Research Base, Winston-Salem
- Wake Forest University Health Sciences, Winston-Salem
- Wake Forest University at Clemmons, Clemmons · 9 mi bort
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekryterarObservationsstudie
- Massive Bio SYNERGY-AI site, Winston-Salem
Icke-småcellig lungcancer-studier i andra städer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andra studier i Winston-Salem
- Cancer (alla typer)19 studier
- Akut myeloid leukemi18 studier
- Multipelt myelom14 studier
- Bröstcancer14 studier
- Hjärt-kärlsjukdom14 studier
- KOL10 studier
- Äggstockscancer10 studier
- Typ 2-diabetes9 studier
- Myelodysplastiska syndrom9 studier
- Glioblastom8 studier
- Kronisk lymfatisk leukemi8 studier
- Lungcancer8 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.